Printer Friendly

APPLIED IMMUNE SCIENCES AND CAREMARK FORM JOINT VENTURE TO ESTABLISH CELL THERAPY CENTERS FOR TREATMENT OF AIDS

APPLIED IMMUNE SCIENCES AND CAREMARK FORM JOINT VENTURE TO ESTABLISH
 CELL THERAPY CENTERS FOR TREATMENT OF AIDS
 MENLO PARK, Calif., Dec. 18 /PRNewswire/ -- Applied Immune Sciences, Inc. (NASDAQ-NMS: AISX) and Caremark Inc., an affiliate of Baxter Healthcare Corporation, announced today the formation of AIS/Caremark Cell Therapy, a joint venture to develop and operate ex vivo cell therapy centers using the AIS CELLector (TM) for treatment of HIV positive and AIDS patients. The joint venture's first cell therapy center -- scheduled to open in the first half of 1992 -- will be established in San Francisco to support Phase II clinical trials.
 The joint venture was formed after encouraging results were achieved in initial human studies in HIV patients using the CELLector-AIDS ex vivo cell therapy. In the Phase I trials, no toxic side effects were seen in any patients and in several cases there were positive responses in HIV related Kaposi's Sarcoma, gastrointestinal disease, and Epstein Barr infections. "We are moving forward with expanded studies to confirm and extend those early clinical findings," said Thomas B. Okarma, Ph.D., M.D., chief executive officer and chief scientist of AIS. "We are delighted to be joining with Caremark, a leading provider of health care services outside the hospital, in a joint venture which, if necessary regulatory approvals are received, will enable us to make our cell therapy available to a larger group of physicians and patients."
 Charles H. Blanchard, president and chief executive officer of Caremark said, "We are excited about joining with AIS to develop its promising new technology. We have planned for sometime to apply our expertise to the area of cell processing. It is an exciting growth opportunity, and AIS is the right partner."
 Caremark is headquartered in Lincolnshire, Ill. The company provides, through its approximately 175 locations, a broad range of sophisticated treatment and therapies to more than 75,000 patients a year with AIDS, cancer, digestive and infectious disease and other life- threatening illnesses. Caremark also services patients with hemophilia and women with high risk pregnancies and related concerns. The company's service alliance division will help develop innovative new drugs through clinical trials and marketing initiatives.
 Applied Immune Sciences, headquartered in Menlo Park, is focused primarily on the development and commercialization of device-based systems for the treatment of immune-related diseases. The company's therapeutic approach is to harvest certain cells or proteins of the patients immune system and manipulate these molecules outside the body using genetically-engineered biologicals. By concentrating the activity of the biological only upon the desired cells or proteins, Applied Immune Science is working to provide a treatment approach that avoids the side effects and limited efficacy associated with systemic administration of the biologials within the body.
 -0- 12/18/91
 /CONTACT: Jim Smith of Applied Immune Sciences, 415-326-7302; Steve Mazur of Caremark, 708-215-3819; or Fred Garcia or Susan Loewe of Clark & Weinstock, 212-953-2550, for Applied Immune Sciences/
 (AISX) CO: Applied Immune Sciences Inc.; Caremark Inc. ST: California, Illinois IN: MTC SU: JVN SM-SH -- NY012 -- 3327 12/18/91 10:28 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 18, 1991
Words:506
Previous Article:CYTOGEN AND KNOLL A.G. CO-MARKETING AGREEMENT FINALIZED
Next Article:PSE&G NAMES NEW CHIEF FINANCIAL OFFICER
Topics:


Related Articles
THE IMMUNE RESPONSE CORP. DISCOVERS T CELLS INVOLVED IN RHEUMATOID ARTHRITIS
IMMUNE RESPONSE FILES INVESTIGATIONAL NEW DRUG APPLICATION FOR NEW RHEUMATOID ARTHRITIS TREATMENT
APPLIED IMMUNE SCIENCES RECEIVES FDA APPROVAL TO BEGIN BREAST CANCER TRIALS
SYSTEMIX ENTERS JOINT VENTURE WITH SANDOZ FOR GENE THERAPY AGAINST HIV
THE IMMUNE RESPONSE CORPORATION AND RHONE-POULENC RORER INC. COMMENCE ARBITRATION
CELL GENESYS ISSUED TWO PATENTS FOR UNIVERSAL DONOR CELL TECHNOLOGY
CELL GENESYS AND JT IMMUNOTECH EXTEND RESEARCH COLLABORATION FOR HUMAN MONOCLONAL ANTIBODIES
INITIAL PHASE I TRIAL OF CELL GENESYS AIDS GENE THERAPY DEMONSTRATES CLINICAL SAFETY
CELL GENESYS FILES IND FOR EXPANDED AIDS GENE THERAPY TRIALS
CELL GENESYS CLEARS FDA FOR EXPANDED AIDS GENE THERAPY TRIALS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters